Ghosh S - Search Results

1

Bioactive natural compounds for the treatment of gastrointestinal disorders.

Ghosh S, Playford RJ. Ghosh S, et al. Clin Sci (Lond). 2003 Jun;104(6):547-56. doi: 10.1042/CS20030067. Clin Sci (Lond). 2003. PMID: 12641494 Review.

2

Is rosiglitazone a promising treatment for ulcerative colitis?

Milestone AN, Iacucci M, Ghosh S. Milestone AN, et al. Among authors: ghosh s. Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):486-7. doi: 10.1038/ncpgasthep1226. Nat Clin Pract Gastroenterol Hepatol. 2008. PMID: 18711416

3

Growth factors and trefoil peptides in gastrointestinal health and disease.

Playford RJ, Ghosh S, Mahmood A. Playford RJ, et al. Among authors: ghosh s. Curr Opin Pharmacol. 2004 Dec;4(6):567-71. doi: 10.1016/j.coph.2004.05.004. Curr Opin Pharmacol. 2004. PMID: 15525545 Review.

4

Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.

Lanzarotto F, Carpani M, Chaudhary R, Ghosh S. Lanzarotto F, et al. Among authors: ghosh s. Drugs. 2006;66(9):1179-89. doi: 10.2165/00003495-200666090-00002. Drugs. 2006. PMID: 16827596 Review.

5

Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease.

van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg AM, Ahmad T, McGovern DP, Onnie C, Negoro K, Goldthorpe S, Foxwell BM, Mathew CG, Forbes A, Jewell DP, Playford RJ. van Heel DA, et al. Among authors: ghosh s. Lancet. 2005 May 21-27;365(9473):1794-6. doi: 10.1016/S0140-6736(05)66582-8. Lancet. 2005. PMID: 15910952

6

Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure.

Cibrián D, Ajamieh H, Berlanga J, León OS, Alba JS, Kim MJ, Marchbank T, Boyle JJ, Freyre F, Garcia Del Barco D, Lopez-Saura P, Guillen G, Ghosh S, Goodlad RA, Playford RJ. Cibrián D, et al. Among authors: ghosh s. Clin Sci (Lond). 2006 May;110(5):563-73. doi: 10.1042/CS20050374. Clin Sci (Lond). 2006. PMID: 16417467

7

Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells--potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation.

Marion-Letellier R, Butler M, Déchelotte P, Playford RJ, Ghosh S. Marion-Letellier R, et al. Among authors: ghosh s. Am J Clin Nutr. 2008 Apr;87(4):939-48. doi: 10.1093/ajcn/87.4.939. Am J Clin Nutr. 2008. PMID: 18400717

8

Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey.

Ghosh S, Mitchell R. Ghosh S, et al. J Crohns Colitis. 2007 Sep;1(1):10-20. doi: 10.1016/j.crohns.2007.06.005. J Crohns Colitis. 2007. PMID: 21172179

9

Management of Crohn's disease from efficacy, quality of life and health economic perspectives.

Ghosh S. Ghosh S. Expert Rev Pharmacoecon Outcomes Res. 2003 Oct;3(5):587-98. doi: 10.1586/14737167.3.5.587. Expert Rev Pharmacoecon Outcomes Res. 2003. PMID: 19807393

10

Hepatosplenic T cell lymphoma in inflammatory bowel disease.

Shale M, Kanfer E, Panaccione R, Ghosh S. Shale M, et al. Among authors: ghosh s. Gut. 2008 Dec;57(12):1639-41. doi: 10.1136/gut.2008.163279. Epub 2008 Jul 30. Gut. 2008. PMID: 18667489 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results